SAN DIEGO, July 11, 2011 /PRNewswire/ — Sequenom, Inc. (NASDAQ:
SQNM), a life sciences company providing innovative genetic
analysis solutions, today announced it has signed a three-year
supply agreement with Illumina, Inc., a leading developer and
manufacturer of life sciences tools for the large-scale analysis of
genetic variation and function.
Under the terms of the agreement, Sequenom and its subsidiaries
will purchase Illumina’s sequencing equipment and consumables for
use in the development of a noninvasive test designed to detect an
overabundance of chromosome 21 in pregnant women, a result
associated with fetal Down syndrome.
Sequenom and Illumina will work collaboratively toward the
submission for regulatory approval of an in vitro diagnostic
product for the detection of fetal chromosomal abnormalities.
“We are pleased to announce this new partnership with Illumina,
a leader in genetic sequencing systems, as we advance our role in
developing and commercializing prenatal diagnostics,” said Harry F.
Hixson, Jr., Chairman and CEO of Sequenom, Inc. “This agreement is
an important step in bringing our proprietary trisomy test to
market, giving us the scalability, speed to market and supply chain
necessary to address the commercial opportunity of our noninvasive
prenatal test for trisomy 21.”
“We are very pleased to complete this supply agreement with
Sequenom for Illumina’s HiSeq 2000 platform,” said Jay
Flatley, President and CEO of Illumina. “With the most powerful and
cost-effective sequencing technology available, we are fully ready
to meet Sequenom’s needs as it prepares for the commercial launch
of its test.”
Sequenom, Inc. (NASDAQ:
SQNM) is a life sciences company committed to improving